Literature DB >> 18325904

Misleading congress about drug development: Reply.

Joseph A Dimasi1, Ronald W Hansen, Henry G Grabowski.   

Abstract

The review essay by Donald Light about a Congressional Budget Office report on pharmaceutical research and development (R&D) (Light 2007) contains factual errors, leaves the reader uninformed about rebuttal responses to criticisms made in the review about studies of R&D costs, and draws erroneous conclusions about the nature of industry economics.

Mesh：

Year:  2008        PMID： 18325904     DOI： 10.1215/03616878-2007-063

Source DB:  PubMed          Journal:  J Health Polit Policy Law        ISSN： 0361-6878            Impact factor:   2.265


  4 in total

Review 1.  Lack of adequate appreciation of physical exercise's complexities can pre-empt appropriate design and interpretation in scientific discovery.

Authors:  F W Booth; M J Laye
Journal:  J Physiol       Date:  2009-09-01       Impact factor: 5.182

2.  The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Authors:  Anita Chawla; Ginger Carls; Edmund Deng; Edward Tuttle
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

3.  The opportunity cost of capital: development of new pharmaceuticals.

Authors:  Ayman Chit; Ahmad Chit; Manny Papadimitropoulos; Murray Krahn; Jayson Parker; Paul Grootendorst
Journal:  Inquiry       Date:  2015-05-01       Impact factor: 1.730

4.  How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.

Authors:  Michael Schlander; Karla Hernandez-Villafuerte; Chih-Yuan Cheng; Jorge Mestre-Ferrandiz; Michael Baumann
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.